The Prognosis of Patients Tested Positive for Stenotrophomonas maltophilia from Different Sources

Figures & data

Figure 1 The mortality of patients with positive S. maltophilia isolates at different sites.

Table 1 Analysis of Mortality of Patients with Positive S. maltophilia Isolates Between Antimicrobial Therapy Group and Non-Antimicrobial Therapy Group at Different Sites [Cases, Rate (%)]

Groups	Deaths (%)		Univariate Analysis
	Antimicrobial Therapy	Non-Antimicrobial Therapy	P value
Blood	8 (18.60)	12 (63.15)	0.001
Urine	1 (3.70)	1 (7.14)	0.632
Peritoneal drainage fluid	9 (18.37)	11 (40.74)	0.034
Alveolar lavage fluid	16 (38.09)	5 (50.00)	0.741
Sputum	55 (24.55)	24 (19.35)	0.268
Wound secretion	5 (11.11)	0 (0.00)	-

Notes: P values less than 0.05 are bolded. Antimicrobial therapy is recommended in the guidelines.²³

Table 2 Analysis of Risk Factors for Mortality in 62 Patients with Positive S. maltophilia in the Blood Culture Group [Cases, Rate (%)]

Items	Univariate Analysis			Multivariate Analysis
	Survival (n=42)	Death (n=20)	P value	OR (95% CI)	P value
Surgery	26(61.90)	5(25.00)	0.007	0.27(0.07, 1.03)	0.056
CRRT	5(11.90)	8(40.00)	0.027	6.86(1.35,34.94)	0.020
Antimicrobial therapy after SMA isolates	35(83.33)	8(40.00)	0.001	0.10(0.02,0.43)	0.002

Notes: P values less than 0.05 are bolded.

Abbreviations: CRRT, continuous renal replacement therapy; SMA, Stenotrophomonas maltophilia.

Table 3 Analysis of Risk Factors for Mortality of Patients with Positive S. maltophilia in Abdominal Drainage Fluid Culture Group[Cases, Rate (%)]

Items	Univariate Analysis			Multivariate Analysis
	Survival (n=56)	Death (n=20)	P value	OR (95% CI)	P value
Age≥65 years	17(30.36)	13(65.00)	0.007	4.96(1.05,23.43)	0.043
Kidney disease	6(10.71)	11(55.00)	0.000	4.62(1.04,20.57)	0.045
Carbapenem exposure	30(53.57)	18(90.00)	0.004	5.39(0.85,34.21)	0.074
Antifungal agent exposure	8(14.29)	8(40.00)	0.036	5.13(1.11,23.72)	0.036
Antimicrobial therapy after SMA isolates	40(71.43)	9(45.00)	0.034	0.42(0.10,1.78)	0.240

Notes: P values less than 0.05 are bolded.

Abbreviation: SMA, Stenotrophomonas maltophilia.

Table 4 Analysis of Risk Factors for Mortality of Patients with Positive S. maltophilia in Sputum Culture Group[Cases, Rate (%)]

Items	Univariate Analysis			Multivariate Analysis
	Survival (n=269)	Death (n=79)	P value	OR (95% CI)	P value
ICU admission	148 (55)	56 (70.9)	0.012	1.22 (0.51, 2.89)	0.653
Kidney disease	56 (20.8)	28 (35.4)	0.008	0.64 (0.35, 1.17)	0.146
Urinary catheterization	188(69.9)	66(83.5)	0.016	0.60 (0.23, 1.58)	0.302
Central venous catheter	166(61.7)	63(79.7)	0.003	0.65 (0.27–1.54)	0.325
CRRT	25(9.3)	21(26.6)	0.000	0.50 (0.24, 1.05)	0.066
Carbapenem exposure	149(55.4)	55(69.6)	0.024	0.77 (0.392, 1.52)	0.455
Glycopeptide exposure	75(27.9)	38(48.1)	0.001	0.53 (0.28, 0.99)	0.045
Antifungal agent exposure	81(30.1)	39(49.4)	0.002	0.51 (0.28, 0.92)	0.024

Notes: P values less than 0.05 are bolded.

Abbreviations: ICU, intensive care unit; CRRT, continuous renal replacement therapy.

Table 5 Analysis of Risk Factors for Death of Patients with Positive S. maltophilia in the Alveolar Lavage Fluid Culture Group[Cases, Rate (%)]

Items	Univariate Analysis			Multivariate Analysis
	Survival (n=31)	Death (n=21)	P value	OR (95% CI)	P value
Age≥65 years	14(45.16)	16(76.19)	0.026	2.90 (0.80, 10.48)	0.105
Diabetes mellitus	2(6.45)	7(33.33)	0.032	5.25 (0.91, 30.20)	0.06

Zhou H, Li GH, Zhuo C, et al. Diagnosis, treatment, prevention and control of Stenotrophomonas Maltophilia infection in China: expert Consensus. National Med J China. 2013;16:1203–1213.

 Google Scholar